Arkolith/Insider Trading/ATHA/Form 4

Litton Mark James

President and CEO, DirectorAthira Pharma, Inc. (ATHA) · full profile →Form 4 · filed Jan 5, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$18K
Net Open-Market Flow
-$18K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 2, 2026Sell(S)3K$6.88$18K41K
Dec 31, 2025Option exercise(M)11K—$043K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 31, 2025Option exercise(M)11K—$00

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001604834-26-000002) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML